U.S. Markets open in 1 hr 43 mins

Fulcrum Therapeutics, Inc. (FULC)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
11.54+0.22 (+1.94%)
At close: 1:00PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close11.32
Open11.22
Bid0.00 x 800
Ask12.50 x 800
Day's Range11.00 - 11.80
52 Week Range7.01 - 22.96
Volume105,271
Avg. Volume209,609
Market Cap316.918M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-14.92
Earnings DateNov 10, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est18.17
  • Here's Why We're Not Too Worried About Fulcrum Therapeutics' (NASDAQ:FULC) Cash Burn Situation
    Simply Wall St.

    Here's Why We're Not Too Worried About Fulcrum Therapeutics' (NASDAQ:FULC) Cash Burn Situation

    Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

  • Fulcrum Therapeutics to Participate in Upcoming Investor Conferences
    GlobeNewswire

    Fulcrum Therapeutics to Participate in Upcoming Investor Conferences

    CAMBRIDGE, Mass., Nov. 13, 2020 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced that management will participate in the following virtual investor conferences: * Stifel Virtual 2020 Healthcare Conference Presentation on Wednesday, November 18, 2020 at 11:20 a.m. ET. * Piper Sandler 32nd Annual Virtual Healthcare Conference Prerecorded Fireside Chat Available on Monday, November 23, 2020 at 10:00 a.m. ETAudio webcasts of the presentations will be available through the Investor Relations section of the Fulcrum website at https://ir.fulcrumtx.com/events-and-presentations. Archived replays will be available on the Company’s website for 90 days after each conference.About Fulcrum Therapeutics Fulcrum Therapeutics is a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases in areas of high unmet medical need. Fulcrum’s proprietary product engine identifies drug targets which can modulate gene expression to treat the known root cause of gene mis-expression. The company has advanced losmapimod to Phase 2 clinical development for the treatment of facioscapulohumeral muscular dystrophy (FSHD) and Phase 3 for the treatment of COVID-19. Fulcrum has also advanced FTX-6058, a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease and beta thalassemia into Phase 1 clinical development.Please visit www.fulcrumtx.com.Contact: Christi Waarich Director, Investor Relations and Corporate Communications 617-651-8664 cwaarich@fulcrumtx.com

  • Novavax (NVAX) Loss Widens in Q3, Revenues Lag Estimates
    Zacks

    Novavax (NVAX) Loss Widens in Q3, Revenues Lag Estimates

    Novavax's (NVAX) bottom line deteriorates year over year in the third quarter of 2020. Revenues fall shy of estimates as well. Stock dips in after-hours trading.